The New Frontier in HIV Pre-exposure Prophylaxis: Lenacapavir Update

Tuesday, October 14, 11:30am - 12:30pm (EDT)

Time shown in-04:00 America, New York

In the ongoing search for new methods to address the HIV epidemic, the development of lenacapavir for HIV prevention is a major step forward. Findings from research studies has shown that twice-yearly injection of long-acting lenacapavir provides protection against HIV infection. This discovery offers great promise in advancing our progress towards ending AIDS as a public health threat.

In this special lecture, Moupali Das, MD, MPH, vice president, Clinical Development, HIV Prevention and Virology Pediatrics, at Gilead Sciences, will provide an update on research findings on lenacapavir for HIV prevention. Her talk will cover the status of the PURPOSE 1-5 studies, review ongoing implementation science studies, and look at the pipeline for pre-exposure prophylaxis (PrEP) at a pivotal moment for the global HIV response

Please fill out the information below to register for the event.

Goingdone
Interestedstar_border
Can't goclear

Full name

Email address

Confirmed.

We've sent a confirmation email to your email address. Be sure to check your junk folder in case you haven't received the confirmation.

Add to Calendar 2025/10/14 11:30:00 2025/10/14 12:30:00 America/New_York The New Frontier in HIV Pre-exposure Prophylaxis: Lenacapavir Update In the ongoing search for new methods to address the HIV epidemic, the development of lenacapavir for HIV prevention is a major step forward. Findings from research studies has shown that twice-yearly injection of long-acting lenacapavir provides protection against HIV infection. This discovery offers great promise in advancing our progress towards ending AIDS as a public health threat.

In this special lecture, Moupali Das, MD, MPH, vice president, Clinical Development, HIV Prevention and Virology Pediatrics, at Gilead Sciences, will provide an update on research findings on lenacapavir for HIV prevention. Her talk will cover the status of the PURPOSE 1-5 studies, review ongoing implementation science studies, and look at the pipeline for pre-exposure prophylaxis (PrEP) at a pivotal moment for the global HIV response 722 West 168th Street, New York, 10032, NY, USA false MM/DD/YYYY 240 OPAQUE a7xnm2g0qzf31831vmeg2139

Confirmed.

We've sent a confirmation email to your email address. Be sure to check your junk folder in case you haven't received the confirmation.

Thank you!

Your changes have been saved. Thanks for keeping us updated.

722 West 168th Street, New York, 10032, NY, USA

Hugh Siegel, icap-communications@columbia.edu

Link: